1. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated;Royston;BMC Med Res Methodol,2016
2. Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models;Freeman;Res Synth Methods,2017
3. Statistical issues and challenges in immuno-oncology;Chen;J Immunother Cancer,2013
4. Non-constant hazard ratios in randomized controlled trials with composite endpoints;Cortés-Martínez;ArXiv190710976 Stat,2019
5. Some statistical considerations in the clinical development of cancer immunotherapies;Huang;Pharm Stat,2018